Počet záznamů: 1  

Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade

  1. 1.
    0461894 - FGÚ 2017 RIV GB eng J - Článek v odborném periodiku
    Vaněčková, Ivana - Řezáčová, Lenka - Kuneš, Jaroslav - Zicha, Josef
    Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade.
    Life Sciences. Roč. 159, Aug 15 (2016), s. 127-154. ISSN 0024-3205. E-ISSN 1879-0631
    Grant CEP: GA MZd(CZ) NV15-25396A
    Institucionální podpora: RVO:67985823
    Klíčová slova: aliskiren * captopril * atrasentan * hypertension * losartan * ren-2 transgenic rats
    Kód oboru RIV: FA - Kardiovaskulární nemoci vč. kardiochirurgie
    Impakt faktor: 2.936, rok: 2016

    We tested whether the addition of ETA blockade to renin-angiotensin system (RAS) blockade would have further effects on the principal vasoactive systems contributing to BP maintenance in Ren-2 transgenic rats (TGR). We found that all RAS blockers similarly decreased BP to normotension, their effects being mediated through substantially attenuated RAS-dependent and moderately decreased SNS-dependent vasoconstriction. Atrasentan alone partially lowered BP, while BP was normalized by combination of atrasentan with either RAS blocker. In combination therapies, BP lowering effects resulted from the attenuation of both RAS- and SNS-dependent vasoconstriction. Moreover, atrasentan-treated groups had substantially reduced NO-dependent vasodilation and significantly decreased calcium influx through L-VDCC. In conclusion, Although the BP-lowering effect of combined ETA and RAS blockades in TGR is predominantly dependent on the effects exerted by RAS blockade, further effects are attributable to decreased calcium influx due to chronic ETA blockade.
    Trvalý link: http://hdl.handle.net/11104/0261451

     
     
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.